Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company ...

本次传出出售博士伦的消息，或许与博士康的当下困境密不可分。据报道，博士康现有债务为210亿美元，其中100亿美元将在2027年底前到期。然而由于博士伦是重要的创收子公司，母公司必须通过偿付能力测试，然后才能批准出售。

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, ...

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial ...

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as ...

Financial writers report on private equity interest in a potential takeover of Bausch & Lomb, with firms like Blackstone and ...

Bausch + Lomb was put up for sale after a planned separation from its parent company Bausch Health, formerly known as Valeant ...

The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its ...

报告预测到2029年全球带状疱疹感染的治疗市场规模将达 亿元，2023至2029期间年均复合增长率为 %。 报告依次分析了Valeant Pharmaceuticals, Novartis, Camber Pharmaceuticals, Teva Pharmaceutical, Abbott等在内的带状疱疹感染的治疗行业内前端企业，同时以图表形式呈现了2020与2024年 ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.